M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Galectin Therapeutics secures patent for combination treatment for use in patients living with liver fibrosis in the US
Therapeutics company Galectin Therapeutics (NasdaqCM:GALT) reported on Monday the receipt of notice of allowance in the US for patent application number 13/550,962 titled 'Galactose-Pronged Polysaccharides in a Formulation for Anti-fibrotic Therapies'.
This notice of allowance was awarded...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives